(Reuters Health)—U.S. public health funding, which covers such things as disease prevention, cancer screenings, contraceptives and vaccines, has been steadily falling in recent years and is expected to keep going down, a recent study projects. Real, inflation-adjusted public health expenditures surged from $39 per capita in 1960 to $281 per capita in 2008, then fell…
U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers
(Reuters)—The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of…
Advocate for Rheumatology with the ACR
Your voice is an essential part of the ACR’s advocacy efforts, and our new Legislative Action Center makes contacting your legislator easier than ever before…
Obama Nominee to Lead FDA Defends Drug Industry Ties
(Reuters)—President Barack Obama’s nominee to head the U.S. Food and Drug Administration defended his ties to the pharmaceutical industry on Tuesday during a Senate committee hearing that included questions on soaring drug prices. Presidential candidate Bernie Sanders was among the Democrats who grilled Dr. Robert Califf (64), who joined the FDA in January as a…
Signatures to Be Filed for California Drug Price Referendum
SACRAMENTO, Calif. (Reuters)—Backers of a referendum aimed at reducing the cost of prescription drugs in California said Wednesday that they had gathered more than enough signatures to place their measure on the November 2016 ballot in the most populous U.S. state. The measure by the AIDS Healthcare Foundation would require the state to pay no…
Specialized Health Care May Be Lacking under Obamacare Plans
(Reuters Health)—Some health insurance plans sold on the Affordable Care Act‘s federal marketplace may not provide reasonable access to medical specialists, new research suggests. Under the act, also known as Obamacare, the federal marketplace offers subsidized private health insurance to consumers in states that didn’t establish their own health insurance exchanges. About one in seven…
Ethics Forum: Personal Ethics Questions Surrounding RheumPAC Donations
Imagine you’ve just heard a compelling presentation urging all ACR members to contribute to RheumPAC, the ACR’s political action committee. RheumPAC’s mission is to support politicians who support issues important to rheumatologists. You are impressed by the role RheumPAC has played in a number of issues you support. Just as you’re writing a check, you…
Why Rheumatologists Should Join the AMA
Editor’s note: Welcome to the first installment of Experiences in Advocacy, a special series authored by ACR members detailing personal experiences in advocacy. We need rheumatologists to join the American Medical Association (AMA). Here’s why, and how to do it. Having participated in your delegation for over a decade, I have seen major improvements in…
Unwelcome News about Medicare’s Rising Drug Plan Costs
CHICAGO (Reuters)—Seniors have received some unpleasant news in their mailboxes in recent weeks: premiums for many Medicare prescription drug insurance plans will rise at double-digit rates next year. Premiums for the ten most popular Medicare Part D prescription drug plans (PDPs) will rise an average of 8 percent next year—the fastest clip in five years,…
Complex Patients More Likely to Switch from Medicare Advantage
NEW YORK (Reuters Health)—Medicare Advantage plans might not be meeting the needs of patients requiring the costliest and most complex levels of care, a new study suggests. Between 2010 and 2011, such patients were more likely to switch from Medicare Advantage plans to traditional Medicare, rather than vice versa, researchers found. The results suggest people…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 86
- Next Page »